These findings provide evidence that signaling gradients set up by cancer cells shape CAF heterogeneity in a way that proximity to tumor cells favors the myCAF phenotype through dominant TGF-β signaling, whereas CAFs that are more distantly to tumor cells rather experience IL-1/IL-1R signaling and thus acquire the iCAF state. The gene discussed is IL1R1; the disease is neoplasm.